A Study to Investigate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of HZBio1 in Healthy Chinese Volunteers
Latest Information Update: 05 Jan 2023
At a glance
- Drugs HZBio 1 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Hangzhou Grand Biologic Pharmaceutical
- 01 Mar 2021 New trial record